Skip to content
Current Assets

Restricted Cash

Neurocrine Biosciences Restricted Cash remained flat by 0.0% to $8M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $8M to $8M.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
Metric ID: restricted_cash

Historical Data

15 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$371.2M$314.3M$278M$171.1M$7.8M$111.6M$168.2M$8M$8M$8M$8M$8M$8M$8M$8M
QoQ Change-15.3%-11.5%-38.5%-95.4%>999%+50.7%-95.2%+0.0%+0.0%+0.0%+0.0%+0.0%+0.0%+0.0%
YoY Change-53.9%-97.5%-59.9%-1.7%+2.6%-92.8%-95.2%+0.0%+0.0%+0.0%+0.0%+0.0%
Range$7.8M$371.2M
CAGR-66.6%
Avg YoY Growth-33.2%
Median YoY Growth-0.8%
Current Streak7 quarters growth

Frequently Asked Questions

What is Neurocrine Biosciences's restricted cash?
Neurocrine Biosciences (NBIX) reported restricted cash of $8M in Q1 2026.
How has Neurocrine Biosciences's restricted cash changed year-over-year?
Neurocrine Biosciences's restricted cash decreased by 0.0% year-over-year, from $8M to $8M.